Skip to main content
Premium Trial:

Request an Annual Quote

Quanterix LucentAD

Quanterix has launched its LucentAD test to aid in the evaluation of patients with cognitive symptoms consistent with early Alzheimer's disease. The test measures phosphorylated tau-181 in plasma, which has been positively correlated with the presences of amyloid pathology in the brain. Quanterix will offer the assay as a lab-developed test run by its CLIA laboratory.